5Jolis L,Carabantes F,Pemas S,et al. Incidence of chemothera- py-induced neutropenia and current practice of prophylaxis with granulocyte colony-stimulating factors in cancer patients in Spain: a prospective, observational study [J]. Eur J Cancer Care,2013,22(4) :513-521.
6Pathak R, Girl S, Aryal MR, et al. Mortality, length of stay, and health care costs of febrile neutropenia-related hospitaliza- tions among patients with breast cancer in the United States [J]. Support Care Cancer, 2(115,23 (3) : 615 -617.
7Chan A,I.ee CP,Chiang J,et al. Breakthrough febrile neutro- penia and associated complications among elderly cancer pa- tients receiving myelosuppressive chemotherapy for solid tumors and lymphomas [J]. Support Care Cancer, 2013, 21 (8) :2137- 2143.
8Dang CT, Fornier MN, Hudis CA. Risk models for neutropenia in patients with breast cancer [J]. Ontology (Williston Park), 2003,17 (11 Suppl 11):14-20.
9Chang LL, Schneider SM, Chiang SC, et al. Implementing an evidence-based risk assessment tool to predict chemotherapy induced neutropenia in women with breast cancer [J]. Cancer Nurs,2013,36 (3) : 198-205.
